Global Retirement Partners LLC Invests $46,000 in Cybin Inc. (NYSE:CYBN)

Global Retirement Partners LLC purchased a new stake in Cybin Inc. (NYSE:CYBN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 5,250 shares of the company’s stock, valued at approximately $46,000.

Analyst Ratings Changes

CYBN has been the subject of several recent research reports. Canaccord Genuity Group dropped their price objective on shares of Cybin from $86.00 to $73.00 and set a “buy” rating for the company in a research report on Wednesday, February 12th. HC Wainwright lowered their price target on Cybin from $190.00 to $150.00 and set a “buy” rating for the company in a report on Thursday, February 13th.

Cybin Price Performance

Shares of NYSE:CYBN opened at $8.16 on Friday. The firm has a market capitalization of $174.27 million, a P/E ratio of -1.86 and a beta of 0.46. The firm has a 50 day moving average price of $9.36. Cybin Inc. has a 52-week low of $6.50 and a 52-week high of $19.85.

About Cybin

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.